Objective To study on Sophora flavescens against hepatitis B virus (HBV) and its mechanism.Methods HepG2.2.15 cells were cultured in vitro, respectively with the negative control group without drug intervention, positive control group (5-Fu group) which was given 0.77 mmol/L 5-Fu, Matrine group treated with 0.77 mmol/L Matrine intervention.HBSAg, HBeAg inhibition rate and cell survival rate, apoptosis rate, cell cycle as observation indexes, comprehensive evaluation of matrine effect on anti 2.2.15 cell HBV in vitro.Results The positive control group, matrine group compared with the negative control group, the inhibition rate of HBsAg and HBeAg were statistically difference ( all P<0.05 ) , when positive control group and Oxymatrine group compared, the inhibition of HBsAg and HBeAg, the difference were statistically (all P<0.05).Cell survival rate, when the positive control group and the negative control group compared, had no significant difference (P<0.05), when matrine group compared with the negative control group, there were significant differences in the survival rate of the cells (t=4.25, P<0.05).Rate of apoptosis cells in negative control group and positive group had not statistically significant, matrine group apoptosis rate was higher than that of the negative control group and the control group (P<0.05).The cells in G0/G1 phase, had no significant differences of distribution in each group, the cells in G2/M phase, the positive control group and matrine group were lower than those in negative control group (P<0.05), matrine group was lower than that of the positive control group (P<0.05).The S phase cells of positive control group and matrine group were higher than those in negative control group (P<0.05), matrine group was higer than that of the positive control group (P<0.05).Conclusion Matrine has obvious effect of anti HBV, inducing cell apoptosis, cell proliferation arrest in S phase.

Objective To observe the clinical efficacy and adverse reactions of intensity modulated radiotherapy (IMRT) combined with cisplatin for patients with carcinoma of cervix.Methods One hundred patients with carcinoma of cervix were randomly divided into 2 equal groups to undergo IMRT only (IMRT group)and IMRT combined group (IMRT with cisplatin chemotherapy group),with 50 cases in each.Both groups were treated with external intensity modulated radiotherapy,with the total dose of 50 Gy,2 Gy/fraetion,25 fractions in total,and 5 times/week.Two weeks later,internal radiotherapy followed,with the total dose of 42-48 Gy,1 time/week with 6-8 times and 6-7 Gy/fraction.When the internal radiotherapy began,the external radiotherapy stopped immediately.The combination group was treated concurrently with cisplatin given by intravenous drip once a week,at the dose of 30-40 mg/m2 body surface area for 4-5 weeks,and with total cisplatin dosage of 50-65 mg.Follow-up was conducted for 18 months(3-60 months).The 1-,3-,and 5-year survival rates,local control rate,distant metastasis rate,and disease-free survival rate,blood test,rectum,and bladder were observed.Results The 1-year survival rate,local control rate,distant metastasis rate,and disease-free survival rate did not differ significantly between these 2 groups,however,the 3-and 5-year survival rates,local control rates,distant metastasis rates and disease-free survival rates of the combination group were all significantly better than those of the IMRT group (x2 =3.843,4.336,4.336,4.960,P ＜ 0.05 ; x2 =3.934,4.454,4.000,4.244,P ＜0.05).The incidence rates of radiation proctitis and leukopenia of the combination group were significantly higher than those of the IMRT only group (x2 =4.110,4.320,P ＜ 0.05),whereas the incidence rates of cystitis,anemia,and thrombocytopenia were not significantly different between these 2 groups.No serious grade 3-4 proctitis and cystitis were observed in these 2 groups.Conclusions The IMRT combined with cisplatin chemotherapy shows higher 3-year and 5-year long-term efficacy in the patients with carcinoma of cervix than IMRT only group.

Objective:To analyze the value of pepsinⅠ( PGⅠ) , pepsinⅡ( PGⅡ) , gastrin-17 ( G-17 ) diagnostic and Helicobacter pylori( Hp IgG) antibody in screening chronic atrophic gastritis and gastric cancer.Methods:90 patients with an upset stomach in our hospital from May 2014 to May 2015 were selected for the study, according to the pathological diagnosis which were divided into normal control group( including chronic non-atrophic gastritis) ,chronic atrophic gastritis group and gastric cancer,30 cases in each group.The level of PGⅠ, PGⅡ, G-17 and Hp IgG antibody positive rate in the three groups of patients were compared.Results:The level of PGⅠ,PGⅡin gastric cancer patients were lower than the control group and chronic atrophic gastritis group.And the index of chronic atrophic gastritis patients were lower than control group.The level of G-17 in gastric cancer group was higher than chronic atrophic gastritis group and the control group, and chronic atrophic gastritis group and the control group had no significant difference.The Hp IgG antibody positive rate in gastric cancer group was significantly higher than other two grups.The level of PGⅠand PGⅡin Hp-infected patients were lower than uninfected Hp patients,and the level of G-17 was higher than uninfected Hp patients.The level of PGⅠ, PGⅡ were significantly negatively correlated with age, pathological stage and metastasis, and positive related with the degree of differentiation;but the level of G-17 and Hp IgG antibody rate were positive related with age,pathological stage and metastasis, and negatively correlated with the degree of differentiation.Conclusion: PGⅠ, PGⅡ and Hp IgG antibody screening have a good diagnostic value in chronic atrophic gastritis and gastric cancer,and better diagnostic value of gastric cancer,G-17 diagnostic value of gastric cancer is much better than the chronic atrophic gastritis;and the level of PGⅠ,PGⅡ,G-17 and IgG antibody positive rate are closely related to the clinicopathological features of gastric cancer patients.

Objective To investigate the changes of fecal short-chain fatty acids (SCFA) and bile acid levels in patients with colon cancer.Methods Totally 189 patients with colon cancer (CC group),201 patients with adenomatous polyp (AP group),and 512 healthy patients (control group) who were confirmed by endoscopy were included in this study.The fecal SCFA and bile acid levels were measured by enzyme linked immunosorbent assay.Results The total bile acids,primary bile acids,and secondary bile acids were not significantly different among these three groups (P ＞ 0.05).The chenodeoxycholate level in the CC group [0.338 (0.101,0.416) mg/g] was significandy higher than that in AP group [0.241 (0.108,0.375) mg/g] and control group [0.248 (0.110,0.371) mg/g] (P=0.025,P=0.023),but was not significantly different between the AP groupand the control group (P ＞ 0.05).The deoxycholic acid level in CC group [0.375 (0.136,0.503) mg/g] and AP group [0.369 (0.113,0.494) mg/g] were significandy higher than that in control group [0.277 (0.115,0.412) mg/g] (P=0.026,P=0.024),and the difference between CC group and AP group was not statistically significant (P ＞ 0.05).The level of lithocholic acid in CC group [0.386 (0.147,0.507) mg/g] was significantly higher than those in the AP group [0.103 (0.012,0.238) mg/g] and control group [0.239 (0.081,0.405) rng/g] (P=0.011,P=0.027); also,its level in AP group was significantly lower than that in the control group (P =0.022).The levels of total short-chain fatty acids,acetic acid,propionic acid,and isovaleric acid were not significantly different among the control group,AP group,and CC group (P＞0.05).The levels of butyrate [0.105 (0.059,0.198) mg/g,0.090 (0.050,0.183) mg/g],isobutyl acid [0.036 (0.024,0.046) mg/g,0.025 (0.020,0.034) mg/g] in CC group and AP group were significantly higher than in the control group [0.081 (0.051,0.107) mg/g,0.021 (0.016,0.029) mg/g] (butyrate:P=0.026,P=0021; isobutyl acid:P=0.025,P=0.019),and the difference between CC group and AP group was statistically significant (butyrate:P =0.031; isobutyl acid:P =0.024).Conclusions Fetal chenodeoxycholic acid,lithocholic acid,butyric acid,and isobutyric acid may play a role in the developmem of colon cancer,while deoxycholic acid may also be implicated in both colon cancer and colon adenomas.No association is found between other SCFA and bile acids and colorectal cancer/adenoma.

BACKGROUND: Recently, some people believed that the mechanisms of primary hepatic carcinoma might be caused by poor differentiation or disdifferentiation of hepatic stem cells. Studies on hepatic stem cells are in the early stage at present, and the theory of "stem cell origins" of human primary hepatic carcinoma deserves further verification. OBJECTIVE: To investigate the activation, distribution, origin and immunological expression characteristics of hepatic stem cells in different histopathologic types of primary hepatic carcinoma. DESIGN: Observational comparative study. SETTING: Tumor Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University of Chinese PLA. PARTICIPANTS: Experiments were performed at the Laboratory of Tumor Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University of Chinese PLA from September 2003 to July 2004. We took 94 cases of hepatic cellular cancer, 12 cases of intrahepatic cholangiocellular carcinoma and 10 cases of mixed hepatocarcinoma paraffin-embedded tissue blocks as research objects, with 5 cases of liver cirrhosis and 4 cases of normal liver as experimental control. These materials were collected from the archive of the Department of Pathology of Daping Hospital. Primary hepatic carcinoma tissues and corresponding adjacent liver tissues were obtained from patients who had undergone surgery for the removal of their tumors. All the patients were not treated by chemotherapy or radiotherapy before the operation. They had signed the informed consent. Main Antibodies were bought from Santa Cruz Company.METHODS: The histological and immunohistochemical characteristics were examined by haematoxylin and eosin staining and immunohistochemistry (SP method), including mouse antihuman cytokeratin 19 monoclonal antibody, mouse antihuman cytokeratin 7 monoclonal antibody, mouse antihuman cytokeratin 8&&18 monoclonal antibody, mouse antihuman c-kit monoclonal antibody, mouse antihuman Thy-1 monoclonal antibody, mouse antihuman alpha fetoprotein monoclonal antibody. MAIN OUTCOME MEASURES: Expression of immunological markers of hepatic stem cells in different histopathologic types. RESULTS: Immunological markers of hepatic stem cells expressed variously in different histopathologic types of primary hepatic carcinoma. Hepatic stem cells differentiated into hepatoma carcinoma cells in all the types. The highest expression rate of hepatic stem cell immunophenotype was found in the mixed hepatocarcinoma (P < 0.05). Immunophenotypes of hepatic stem cells were negative in normal group and cirrhosis group. CONCLUSION: Hepatic stem cells of varied differentiations and origins existed in different histopathologic types of primary hepatic carcinoma.